Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pan-cancer pharmacogenetics: targeted sequencing panels or exome sequencing?

Pharmacogenomics - 1 Oct 2020

Tilleman Laurentijn, Heindryckx Björn, Deforce Dieter, Van Nieuwerburgh Filip

Abstract excerpt

Aim: This study provides clinicians and researchers with an informed choice between current commercially available targeted sequencing panels and exome sequencing panels in the context of pan-cancer pharmacogenetics. Materials & methods: Nine contemporary commercially available targeted pan-cancer panels and the xGen Exome Research Panel v2 were investigated to determine to what extent they cover the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Databases, Genetic
Share to Exome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exome Sequencing

Share to High-Throughput Nucleotide Sequencing

Share to Neoplasms

Share to Pharmacogenetics

Share to Pharmacogenomic Testing

Source

Identifiers

PMID: 33019866
DOI: 10.2217/pgs-2020-0035

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pan-cancer pharmacogenetics: targeted sequencing panels or exome sequencing?PMID 33019866Read ↗

Integrating Somatic and Germline Pharmacogenomics for Therapeutic Decisions in Precision Oncology.Semantic proximity Read ↗

Translational and clinical comparison of whole genome and transcriptome to panel sequencing in precision oncologySemantic proximity Read ↗

Cancer driver genes and opportunities for precision oncology revealed by whole genome sequencing 10,478 cancersSemantic proximity Read ↗

Cancer driver genes and opportunities for precision oncology revealed by whole genome sequencing 10,478 cancersSemantic proximity Read ↗

Targeted therapy according to next generation sequencing-based panel sequencingSemantic proximity Read ↗

Utilizing Targeted Enhanced-Whole-Genome Sequencing in Precision Oncology for the Treatment of Solid Tumors: A Clinical PerspectiveSemantic proximity Read ↗

Personalized cancer care.Semantic proximity Read ↗

Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels.Semantic proximity Read ↗

Clinical and Technical Validation of OncoIndx® Assay – A Comprehensive Genome Profiling Assay for Pan-Cancer InvestigationsSemantic proximity Read ↗

Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data.Semantic proximity Read ↗

Personalized genomic analyses for cancer mutation discovery and interpretation.Semantic proximity Read ↗

Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.